ROPAD Study of Parkinson’s Genetics Enrolling 2,500 More Patients

ROPAD Study of Parkinson’s Genetics Enrolling 2,500 More Patients

293980

ROPAD Study of Parkinson’s Genetics Enrolling 2,500 More Patients

Centogene announced plans to recruit 2,500 more patients this year into its observational Rostock International Parkinson’s Disease (ROPAD) study of how genetic factors contribute to the development of Parkinson’s. “We recently reached a significant study milestone, but this is just the beginning,” Peter Bauer, MD, Centogene’s chief genomic officer, said in a press release. “By extending this study … we will be able to unveil deeper data on Parkinson’s disease genetics, diagnose patients earlier, and accelerate…

You must be logged in to read/download the full post.